NIFTY SUPPORT ON 05/12/2017
|
|||||
Pivot |
R1 |
R2 |
S1 |
S2 |
|
Nifty |
10134
|
10173
|
10218 |
10089 |
10051
|
Bank Nifty |
25122 |
25250
|
25426
|
24947 |
24818
|
Turnover(cr)
|
NSE
&BSE(Total value)
(Rs.
Cr)
|
||
INDEX
FUTURES
|
14,425.97
|
FII
|
-333.59
|
INDEX
OPTIONS
|
3,09,736.18
|
DII
|
776.18
|
STOCK
FUTURES
|
38,883.17
|
Put Call
Ratio 0.81
|
|
STOCK
OPTIONS
|
22,820.62
|
Market Volume (in Rs Crore)
|
|
NSE CASH |
28,450.31 |
NSE F&O |
441,292.94 |
Zydus Cadila gets USFDA approval: The company has received the final approval from the USFDA to market Doxycycline Hyclate Delayed-Release Tablets USP in the strengths of 75 mg, 100 mg and 150 mg.
ReplyDeleteCapitalstars